CStone Pharmaceuticals
Jingru Wang has extensive experience in the pharmaceutical industry, with their most recent position being Senior Director of Clinical Development at CStone Pharmaceuticals since October 2022. Prior to that, they held roles such as Director of Clinical Development and Associate Director of Clinical Science at the same company. Before joining CStone Pharmaceuticals, Jingru worked at Eli Lilly China, where they gained experience as a Scientist III, Scientist II, and Scientist I. Jingru began their career as a Senior Research Assistant at the Shanghai Institute of Medical Materiia, Chinese Academy of Sciences.
Jingru Wang holds a Doctor of Philosophy degree in Neuropharmacology from Shanghai Institute of Materia Medica, CAS, which was completed from 2005 to 2009. Prior to that, Jingru Wang obtained a bachelor's degree in Pharmaceutical Science and Technology from Jilin University from 1998 to 2002. Additionally, from 2002 to 2004, Jingru Wang attended Shenyang Pharmaceutical University and earned a Master's degree.
CStone Pharmaceuticals
CStone is a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established at the end of 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. With a strategic emphasis on immuno-oncology combination therapies, the Company has built an oncology-focused pipeline of 16 drug candidates, including 5 late-stage candidates at pivotal trials or registration stages. With an experienced team, a rich pipeline, a robust clinical development-driven business model and substantial funding, CStone’s vision is to become a world-renowned biopharmaceutical company that is leading the way to conquering cancer.